Helus Pharma™’s Breakthrough-Designated Depression Drug HLP003 Completes 86% Enrollment in Phase 3 Trial, Topline Data Expected Q4 2026

July 5, 2026

PR Newswire Unknown

Overview

Helus Pharma™’s APPROACH Phase 3 trial for HLP003, an investigational adjunct therapy for major depressive disorder (MDD), has successfully completed over 86% of patient enrollment. HLP003 has received Breakthrough Therapy designation from the U.S. FDA, and the company anticipates announcing topline data in Q4 2026. Phase 2 results demonstrated a significant reduction of approximately 23 points in MADRS scores at 12 months, highlighting its potential as a breakthrough in depression treatment.

In Depth

Key Findings

Helus Pharma™’s APPROACH Phase 3 clinical trial for HLP003, an investigational adjunctive therapy for major depressive disorder (MDD), has successfully completed over 86% of patient enrollment and is progressing as planned. HLP003 has been granted Breakthrough Therapy designation by the U.S. FDA, and the company is scheduled to announce topline data in Q4 2026, generating significant anticipation for a new treatment option in depression.

Technical/Clinical Details

HLP003 is a novel investigational therapeutic candidate for patients with major depressive disorder who have not achieved adequate response with existing antidepressants. Its mechanism of action is believed to involve modulating brain neural circuits and neurotransmitter systems through an approach distinct from conventional drugs, aiming to alleviate depressive symptoms. This trial is designed to evaluate whether HLP003, when used in combination with existing antidepressants, can further reduce depressive symptoms. Previous Phase 2 clinical trials demonstrated a statistically significant and clinically meaningful improvement, with patients receiving HLP003 showing approximately a 23-point reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores at 12 months. A 23-point reduction on the MADRS score indicates a significant recovery from severe depressive symptoms. The Breakthrough Therapy designation from the FDA is based on this preliminary clinical data suggesting the potential for substantial improvement over existing therapies for the serious condition of MDD. This designation accelerates the development and review process for HLP003.

Background & Context

Major depressive disorder is one of the most common mental illnesses globally, with high prevalence rates that severely impair patients’ quality of life. While existing antidepressants are effective, many patients achieve only partial response or exhibit treatment resistance, leaving a significant unmet medical need. The introduction of new adjunctive therapies is particularly crucial for improving treatment outcomes and achieving remission in a greater number of patients. The Breakthrough Therapy designation for HLP003 reflects strong expectations for innovation in this disease area.

Strategic Significance & Outlook

The announcement of topline data from the APPROACH Phase 3 trial for HLP003 will be one of the most anticipated events in psychiatry. If positive results are demonstrated, HLP003 has the potential to become a new standard of care as an adjunctive therapy for MDD, benefiting many patients with treatment-resistant depression. With Breakthrough Therapy designation, the FDA is expected to expedite the review process, leading to a potentially earlier market entry. This success will deepen the understanding of the complex pathology of depression and further stimulate the development of psychiatric drugs with novel mechanisms of action, injecting new vitality into the entire field of psychiatry.

Source: https://www.prnewswire.com/news-releases/a-breakthrough-designated-depression-drug-is-86-through-its-phase-3-with-topline-data-due-this-year-302811862.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.